Novo Nordisk Launches Wegovy Pill, Expanding Patient Choice and Access with knownwell as a Recognized NovoCare Provider

Novo Nordisk has launched the Wegovy pill, the first oral GLP-1 option for chronic weight management approved by the FDA. The introduction of an oral formulation expands patient choice and access to evidence-based obesity treatment. knownwell, a weight-inclusive primary care and metabolic health company, is recognized as a NovoCare provider, offering comprehensive, longitudinal obesity care for patients seeking treatment with real FDA-approved products, including the Wegovy pill.